Providing cost-effective care for food allergy

Ann Allergy Asthma Immunol. 2019 Sep;123(3):240-248.e1. doi: 10.1016/j.anai.2019.05.015. Epub 2019 May 23.

Abstract

Objective: To review the cost-effectiveness of food allergy management strategies.

Data sources and study selections: A narrative review and synthesis of literature identified using a PubMed search of relevant articles describing cost-effectiveness evaluations of food allergy management.

Results: Screening at-risk infants for peanut allergy carries risk of overdiagnosis and is not cost-effective. Evidence suggests that cost-effective care could be better optimized by minimizing delay in oral food challenges for eligible patients, clarifying the role of precautionary allergen labeling, incorporating patient-preference sensitive care in activation of emergency medical services for resolved allergic reactions, and considering value-based pricing and school-supply models for epinephrine. Finally, the annual value-based cost (willingness to pay [WTP] $100,000/quality-adjusted life years [QALY]) of peanut immunotherapy has been estimated to be between $1568 and $6568 for epicutaneous immunotherapy (EPIT) and between $1235 and $5235 for probiotic with peanut oil immunotherapy (POIT), with each therapy showing more favorable cost-effectiveness with greater improvements in health utility, particularly if sustained unresponsiveness can be achieved.

Conclusion: Many aspects of food allergy management are not cost-effective, and recent evaluations suggest a greater role for incorporating patient and family preferences into guideline-based and traditionally reflexive management decisions. Caregiver understanding of food allergy screening tradeoffs is critical, given that screening children before allergen exposure has significant costs and results in overdiagnosis, especially when oral food challenges are omitted from diagnostic algorithms. Cost-effectiveness analysis can help to identify important decision levers in patient management across a wide range of topics. Further research is needed to better understand health state utilities of specific patient populations.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Allergens / immunology
  • Allergens / therapeutic use*
  • Arachis / immunology
  • Biological Therapy / economics*
  • Cost-Benefit Analysis
  • Desensitization, Immunologic / economics*
  • Emergency Medical Services
  • Food Hypersensitivity / economics
  • Food Hypersensitivity / therapy*
  • Food Labeling
  • Humans
  • Immune Tolerance
  • Probiotics / therapeutic use*
  • Quality-Adjusted Life Years

Substances

  • Allergens